Storia in 6 fonti

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.

Raccontata da

pharmaceutical-technology.com

biopharmadive.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

pharmaceutical-technology.comStai leggendo1 mesi fa

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical…

Akeso's ivonescimab bispecific achieved 34% death risk reduction in squamous NSCLC; Eli Lilly expanded Retevmo (RET TKI) to adjuvant early-stage disease. Both mark competitive reshaping of NSCLC, with Idafang projected at $11bn global sales by 2032.

originale

Timeline cronologica

domenica 31 maggio 2026·fiercepharma.com
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant…
domenica 31 maggio 2026·fiercebiotech.com
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data…

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology

Confronto fonti

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical…

Timeline cronologica

ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior…

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

ASCO26: In vivo oncology approaches continue to show promise

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology